Scared of needles? Here’s some good news: in the future, you might be able to rub a vaccination into your skin.
Researchers at the University of Auckland have found a way to deliver medicines through skin, which is usually an impervious barrier.
“It’s like wearing a raincoat – it stops the water getting in, we go out in the rain and we don’t melt, stops all those nasty chemicals getting through our skin most of the time,” says Dr Dareen Svirskis, senior pharmacy lecturer.
“This is potentially a breakthrough peptide technology,” says Professor Julia Kennedy, head of Auckland University’s School of Pharmacy. “Obtaining a biological response from applying substances through the skin is very difficult to achieve and approaches can be extremely expensive.”
For the past four years senior pharmacy lecturer Zimei Wu has been supervising research by PhD candidate Travis Badenhorst, with the assistance of Dr Svirskis. Dr Svirskis says their breakthrough allows drugs to be delivered directly to cells through the skin.
“What Zimei’s envisaged is to develop this tiny little nano formulation, these tiny little nano carriers. We can put the peptide inside that, and what’s amazing is that we’ve seen for the first time that it can be delivered to the skin, it’ll pass through the skin and it’ll be taken up in cells.
“We’ve seen this in cell cultures for the first time biologically, and we’ve seen this in human skin as well.”
The research was financially backed by the Government and Auckland-based skincare company Snowberry, which has applied for a patent on the process.
And there’s a good reason a cosmetics company backed the research – Dr Svirskis says the technology is perfect for anti-aging products, and outperformed every existing commercial product they compared it to during testing.
“The cosmetic route’s a lot faster to get a product to people. When we start talking about medical devices or vaccine delivery, then yes, there’s years of testing they have to go through to ensure the safety and efficacy of these products.”
Read more: Medical breakthrough threatens to banish needles forever
The Latest on: Peptide technology
[google_news title=”” keyword=”Peptide technology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Peptide technology
- Fresh hope for chronic woundson May 8, 2024 at 7:44 am
Peptides and proteins typically degrade and break down under ... That’s the nature of invention. OEIP Technology Transfer specialists, however, continued building relationships with companies that ...
- AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)on May 6, 2024 at 5:00 am
The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 ...
- Global Peptide Therapeutics Industryon May 2, 2024 at 5:21 am
Global Peptide Therapeutics Industry is valued at US$ 38.0 Bn for 2023 & expected to reach US$ 106.0 Bn by 2033 at a CAGR of 10.8% by 2033.
- PeptiDream expands peptide discovery collaboration with Novartison May 2, 2024 at 3:00 am
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG. Under the multi-programme ...
- Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bnon May 2, 2024 at 12:11 am
Novartis and PeptiDream have expanded their peptide discovery collaboration with a new agreement worth over $2.8bn. The multi-programme agreement will see PeptiDream use its proprietary Peptide ...
- Antimicrobial Peptide From Cows Has Potential To Treat Incurable Bacteria Infectionon May 1, 2024 at 5:00 pm
In a study published recently in Cell Reports Physical Science, Fleeman showed that an antimicrobial peptide from cows has potential for treating incurable infections from the bacterium Klebsiella ...
- Novartis and PeptiDream expand peptide discovery dealon May 1, 2024 at 3:49 am
Novartis and Japanese biopharmaceutical company PeptiDream have expanded their partnership for the discovery of peptides.
- Novartis, Peptidream expand peptide discovery effort in $2.7B dealon April 30, 2024 at 5:00 pm
Under the multi-program agreement, Kawasaki, Japan-based Peptidream will use its peptide discovery platform system technology to identify and optimize novel macrocyclic peptides against targets ...
- Altimmune gets grant for pharmaceutical composition of peptides for HBV treatmenton April 30, 2024 at 5:39 am
Discover Altimmune Inc's groundbreaking patent for a pharmaceutical composition targeting HBV with peptides containing CD8+ and CD4+ T-cell epitopes. Learn about the innovative intracellular delivery ...
- PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartison April 30, 2024 at 4:00 am
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide ...
via Bing News